Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07248839 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT07248839 is a Phase 1 study that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants.
The verdict
NCT07248839, a Phase 1 study, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants with different degrees of hepatic impairment
Interventions
- DRUG BMS-986435
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-12-15 |
| Est. Completion | 2026-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07248839
The ClinicalTrials.gov registry entry for NCT07248839 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986435 is the first listed.
NCT07248839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07248839 about?
NCT07248839 is a clinical study titled "A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment". The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants with different degrees of hepatic impairment
What is the current status of trial NCT07248839?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-12-15. Estimated completion is 2026-08-05.
What interventions are being tested in trial NCT07248839?
The interventions under investigation include: BMS-986435 (DRUG).
Who is sponsoring clinical trial NCT07248839?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.